FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide)

[8-24-2011] The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and patients that the antidepressant Celexa (citalopram hydrobromide; also marketed as generics) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Source Type: news

Related Links:

Publication date: Available online 27 June 2019Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): W.B. Kretschmer, G. BaciuĊ£, M. BaciuĊ£, R. SaderAbstractWe investigated the effect of bimaxillary orthognathic surgery on symptoms in the temporomandibular joint (TMJ) and predictive factors for postoperative dysfunction. A total of 500 patients with different craniofacial deformities who were having bimaxillary orthognathic surgery were assessed for overjet, overbite, maximal mouth opening, maximal protrusion, maximal lateral movement to both sides, and symptoms of TMJ dysfunction (pain on palpation, clickin...
Source: British Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Source Type: research
Publication date: Available online 27 June 2019Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): C.J. Henry, M. Halligan, A. Bozic, C.P. Barry
Source: British Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Source Type: research
Macleods Pharmaceuticals Limited has initiated a voluntary recall in the United States, to the patient level, of 32 lots of Losartan Potassium USP Tablets (2 lots of 50mg strength) and Losartan Potassium/Hydrochlorothiazide combination Tablets
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
The Food and Drug Administration (FDA or the Agency) is announcing a public workshop to discuss the present state of understanding of pediatric ontogeny as it pertains to pediatric drug development. The workshop aims to address the incomplete information available on the ontogeny of several relevant
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Guidance for Industry
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
C. Das, G. Ghosh, A. Bose and D. Das*
Source: Indian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research
Preeti P. Mehta*, A. R. Chabukswar and Swati C. Jagdale
Source: Indian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research
K. K. Mali*, Sucheta S. Ligade and R. J. Dias
Source: Indian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research
Q. P. Liang, C. Wu, T. Q. Xu, X. Y. Jiang, G. D. Tong, C. S. Wei and G. X. Zhou*
Source: Indian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research
J. Chimakurthy*, T. E. G. K. Murthy and P. V. Diwan
Source: Indian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Celexa | Citalopram | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart